1995
DOI: 10.1016/0016-5085(95)90196-5
|View full text |Cite
|
Sign up to set email alerts
|

Prognosis of patients with nonmalignant chronic intestinal failure receiving long-term home parenteral nutrition

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

9
82
2
6

Year Published

1996
1996
2015
2015

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 206 publications
(99 citation statements)
references
References 16 publications
9
82
2
6
Order By: Relevance
“…78% of those who survive with the transplant are able to stop parenteral nutrition. These figures contrast to those for patients on home parenteral nutrition for non-neoplastic reasons who can expect to have a relatively good quality of life good and a survival rate of 70% at 3 years [223,224] .…”
Section: New and Future Treatmentsmentioning
confidence: 65%
“…78% of those who survive with the transplant are able to stop parenteral nutrition. These figures contrast to those for patients on home parenteral nutrition for non-neoplastic reasons who can expect to have a relatively good quality of life good and a survival rate of 70% at 3 years [223,224] .…”
Section: New and Future Treatmentsmentioning
confidence: 65%
“…46,48,49,83,152,[156][157][158] Survival is principally determined by underlying disease; patients with inflammatory bowel disease for example demonstrate a high 5-year survival of 92%, 157 whereas patients with motility disorders have the poorest 5-year survival at 48%. 157 Multivariate analysis of survival data from single centres has also demonstrated lower survival rates in patients with end-enterostomies 156,158 or a small bowel length of <50 cm. 156 The survival of patients receiving PN for advanced malignancy is poor with median time to death of between 5 and 6.5 months.…”
Section: Survivalmentioning
confidence: 99%
“…157 Multivariate analysis of survival data from single centres has also demonstrated lower survival rates in patients with end-enterostomies 156,158 or a small bowel length of <50 cm. 156 The survival of patients receiving PN for advanced malignancy is poor with median time to death of between 5 and 6.5 months.…”
Section: Survivalmentioning
confidence: 99%
“…achieving enteral autonomy) and decreasing rates and progression of intestinal failure-associated liver disease (IFALD) and other life-threatening complications in patients remaining on PN. Historically, life-threatening complications and the underlying disease led to mortality of up to 38% within 2-5 years following the development of intestinal failure (3)(4)(5)(6). In a contemporary series, for patients without complications marked improvement in survival was demonstrated with 87% of PN-dependent patients achieving 5-year patient survival (7).…”
Section: Purpose Of Reviewmentioning
confidence: 99%